Newron Pharmaceuticals S.p.A. (SWX: NWRN)
Switzerland
· Delayed Price · Currency is CHF 8.81
-0.14 (-1.56%)
Jan 3, 2025, 5:31 PM CET
Newron Pharmaceuticals Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 6.97 | 6.79 | 5.95 | 5.76 | 5.26 | 7.04 | Upgrade
|
| Other Revenue | - | 2.26 | 0.14 | - | - | - | Upgrade
|
| Revenue | 6.97 | 9.06 | 6.09 | 5.76 | 5.26 | 7.04 | Upgrade
|
| Revenue Growth (YoY) | -20.42% | 48.62% | 5.76% | 9.59% | -25.29% | 74.86% | Upgrade
|
| Gross Profit | 6.97 | 9.06 | 6.09 | 5.76 | 5.26 | 7.04 | Upgrade
|
| Selling, General & Admin | 8.06 | 7.53 | 7.39 | 7.39 | 8.47 | 10.5 | Upgrade
|
| Research & Development | 13.92 | 13.15 | 12.01 | 10.73 | 14.85 | 17.44 | Upgrade
|
| Operating Expenses | 21.98 | 20.69 | 19.4 | 18.12 | 23.32 | 27.94 | Upgrade
|
| Operating Income | -15.01 | -11.63 | -13.3 | -12.36 | -18.07 | -20.9 | Upgrade
|
| Interest Expense | -4.32 | -4.17 | -3.95 | -2.92 | -2.24 | -0.57 | Upgrade
|
| Interest & Investment Income | 0.18 | 0.18 | 0.06 | 0.05 | 0.06 | 0.19 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.11 | -0.07 | 0.12 | 0.2 | -0.17 | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.45 | -0.51 | -0.4 | 0.13 | 0.79 | 1.14 | Upgrade
|
| EBT Excluding Unusual Items | -18.81 | -16.2 | -17.47 | -14.88 | -19.62 | -20.16 | Upgrade
|
| Pretax Income | -18.81 | -16.2 | -17.47 | -14.88 | -19.62 | -20.16 | Upgrade
|
| Income Tax Expense | 0.03 | 0.02 | 0.02 | 0.02 | 1.38 | 0.05 | Upgrade
|
| Net Income | -18.83 | -16.22 | -17.49 | -14.9 | -21 | -20.21 | Upgrade
|
| Net Income to Common | -18.83 | -16.22 | -17.49 | -14.9 | -21 | -20.21 | Upgrade
|
| Shares Outstanding (Basic) | 18 | 18 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 18 | 18 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Change (YoY) | 2.01% | - | - | - | - | 0.01% | Upgrade
|
| EPS (Basic) | -1.03 | -0.91 | -0.98 | -0.84 | -1.18 | -1.13 | Upgrade
|
| EPS (Diluted) | -1.03 | -0.91 | -0.98 | -0.84 | -1.18 | -1.13 | Upgrade
|
| Free Cash Flow | -13.38 | -10.15 | -11.11 | -11.47 | -15.62 | -22.03 | Upgrade
|
| Free Cash Flow Per Share | -0.73 | -0.57 | -0.62 | -0.64 | -0.88 | -1.23 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -215.29% | -128.40% | -218.28% | -214.46% | -343.59% | -296.95% | Upgrade
|
| Profit Margin | -270.17% | -179.13% | -287.05% | -258.61% | -399.35% | -287.11% | Upgrade
|
| Free Cash Flow Margin | -191.89% | -112.08% | -182.31% | -198.98% | -297.11% | -312.97% | Upgrade
|
| EBITDA | -14.88 | -11.49 | -13.27 | -12.31 | -17.99 | -20.85 | Upgrade
|
| EBITDA Margin | -213.41% | -126.89% | -217.67% | -213.64% | - | -296.21% | Upgrade
|
| D&A For EBITDA | 0.13 | 0.14 | 0.04 | 0.05 | 0.07 | 0.05 | Upgrade
|
| EBIT | -15.01 | -11.63 | -13.3 | -12.36 | -18.07 | -20.9 | Upgrade
|
| EBIT Margin | -215.29% | -128.40% | -218.28% | -214.46% | - | -296.95% | Upgrade
|
| Revenue as Reported | 6.97 | 9.06 | 6.09 | 5.76 | 5.26 | 7.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.